Financial PerformanceThe mid-term earnings growth outlook for Roche is projected at 4%, which is lower compared to sector peers at 8%.
Market ChallengesVabysmo missing consensus expectations by approximately 8% will likely be a focus point for investors, and the shares are expected to underperform.
Sales PerformanceA more challenging US market for Vabysmo drives FY25 sales growth closer to 18% YoY, compared to the pre-Q1 consensus of around 33% growth.